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This study aimed to evaluate the effects of micron sized non-thermal atmospheric pressure plasma 
inside the animal body on breast cancer tumor. The μ-plasma jet consists of micron sized hollow tube 
in which pure helium gas is ionized by high voltage (4 kV) and high frequency (6 kHz). The efficiency 
of the plasma treatment in killing cancer cells was first investigated by cell viability measurements of 
treated 4T1 cells using flow cytometry and cell cycle analysis. For exploration of the in vivo effects of 
the plasma treatment, the BALB/c mice inoculated by 4T1 cell lines were exposed subcutaneously to 
plasma for 3 minutes. In addition, H&E staining, TUNEL and Western blotting assays were performed 
in order to observed the effects of the non-thermal plasma on the tumor cells. The results showed 
that the efficiency of the plasma in suppression of the tumor growth is comparable to that of a typical 
chemotherapy drug. Moreover, the results indicated that the plasma induces apoptosis in the tumor 
tissue and increases the ratio of the apoptotic to anti-apoptotic protein expression. We believe that 
these findings presented herein may extend our knowledge of the mechanisms by which the plasma 
exerts its promising anti-cancer effects.
The cancer treatment by non-thermal atmospheric pressure plasma has attracted considerable attentions to the 
field of cancer therapy by using cold plasma1–5. The conventional cancer therapy techniques are associated with 
many issues such as the normal tissue damage, time consuming treatment procedure and expensive therapies6. 
The non-thermal plasma treatment has been introduced as a cost effective, rapid and low damage treatment 
which may represent an alternative for the conventional methods. Plasma contains the reactive species7,8, free 
radicals9, energetic ions10 and also the transient electric fields inherent with plasma delivery11,12 which are formed 
in the atmospheric room temperature medium and interact with the cells and other living organisms. It was 
shown that the plasma induced the apoptotic cell death in cancer cells while it had no adverse effect on the normal 
cell lines in the appropriate dosage13,14. The results also indicated that by exposing the free radicals to cancer cells, 
the cells could produce the intracellular reactive oxygen species (ROS) which could cause apoptotic cell death15. 
In addition, the role of nitric oxide (NO) generated by plasma is considerable16,17. Moreover many other studies 
tried to figure out the mechanism of the cell death in cancer cells treated by the non-thermal plasma such as the 
cell signals activation induced by the reactive agents18–21. Meanwhile, few studies have presented the effect of 
non-thermal plasma on the in-vivo tumor models22,23. The reports have shown the tumor suppression with differ-
ent dosage of the plasma treatment23. The researchers also tried to figure out the mechanism of the plasma tumor 
interaction23,24. One of the benefits of the plasma treatment in the in-vivo model is that the plasma has low harm 
effects on the normal tissue in the appropriated dosages25.
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One of the aims of the plasma medicine is to employ the atmospheric plasma jet inside the living creature’s 
body. The atmospheric pressure plasma is not applicable for cancer therapy in the conventional form, because 
of some major drawbacks such as the plasma probe volume, high voltage issue, gas delivery and the formation 
of discharge in the organ. Moreover the heat inside the organ should be controllable and should not harm the 
normal tissues. Some studies were done to utilize the atmospheric plasma inside the body by miniaturization of 
the plasma in the micron sized probe26,27. In addition some other researchers investigated the optimization of the 
atmospheric pressure plasma devices in the μ -sized shape both in the helium jet and the dielectric barrier dis-
charge forms in order to conduct the plasma species to the living animals28–30. Furthermore, the researchers tried 
to employ the μ -sized plasma jet for a single cell therapy26. However, these studies were not completely successful 
for carrying out the atmospheric plasma treatment inside the animal body.
This study aimed to perform the plasma treatment inside the animal model and to evaluate the efficiency 
of micron-sized non-thermal atmospheric pressure plasma on the tumor growth suppression. In this regards, 
followed by the fabrication and characterization of the μ -plasma, the possible mechanisms of the in vitro and 
in vivo plasma-cancer cells interactions were further investigated.
Results
Plasma characterization. Figure 1a represents the species generated in the plasma. Results show that reac-
tive particles of the oxygen atom (777 nm) and OH (310 nm) are of the most important constituents of plasma. 
From the analyzing of the nitrogen second positive system, ranging from 370 nm to 382 nm, electron temperature 
of 4000 ± 300 K and ion temperature of 300 ± 5 K were obtained (Fig. 1b). The plasma density was obtained as 
(4.8 ± 1.2) × 1013 


cm
1
3  from the analyzing the Hα line broadening (Fig. 1c).
Plasma inhibits the metastasis of the cancer cells. Figure 2 represents the scratch test result 24 hours 
after the plasma or drug treatments. According to the results, in the case of the untreated cells, about 64% of 
the scratched area was covered by migrated cell in 24 hours; whereas, only 18% of the cells in the wound area 
grew within 24 h after plasma radiation (t(10) = 2.76, P < 0.01). With respect to the drug treatment, this amount 
reached 23% in comparison to untreated cells (t(10) = 2.76, P < 0.01).
Plasma induces apoptosis in the cancer cells. Figure 3a represents the ability of plasma to induce apop-
tosis in cancer cells based on flow cytometry results. This diagram shows that after plasma treatment, the cells 
Figure 1. (a) Optical emission spectroscopy of the μ -plasma jet in the range of 200–1000 nm. (b) Ion and 
electron temperature analyses of the nitrogen SPS experiment. (c) Analyses of the Hα transition band for 
evaluation of the plasma electron density.
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migrate from the live zone to apoptotic zone. According to this diagram, more than 80% of the cells underwent 
apoptosis after plasma radiation (t(10) = 4.14, compared to the untreated group, P < 0.001). This amount was 
less than 3% for drug treatment (t(10) = 1.81, compared to the untreated group, P < 0.05). It is worth noting that 
in the drug treatment, cells underwent the necrosis (23.3%, t(10) = 2.76, P < 0.01). Figure 3b represents the cell 
cycle analysis after plasma radiation. These results indicate that half of the cells remained in SubG1 phase after 
plasma radiation (t(10) = 4.14, P < 0.001) while this amount was about 20% after drug treatment (t(10) = 2.76, 
P < 0.01). In addition less than 35% of the cells remain in the G0/G1 stage after the plasma treatment in compari-
son to the untreated samples (t(10) = 2.76, P < 0.01). This value reaches to 50% in the drug treated cells compared 
to the untreated samples (t(10) = 2.76, P < 0.01). Finally, there is no significant change in the population of the S 
phase cells in the case of plasma treatment and G2/M phase in both plasma and drug treatment compared to the 
untreated samples (P > 0.05).
Plasma suppressed the tumor growth in the animals. Figure 4a represents the tumor size after plasma 
radiation at different days following the plasma treatment. This diagram shows no significant difference between 
the treated (by plasma and doxorubicin) and untreated groups up to 14 days after the treatment (P > 0.05), while 
after the day of the 16, the tumor suppression induced by plasma significantly differed from untreated sample 
(F(2,15) = 11.33, P < 0.001). The tumor size dramatically increased in the control group, insofar as it reached 
500 mm3 on the 16th day (compared to day 0, P < 0.001) and almost 2000 mm3 after 24 days (compared to day 
0, P < 0.001); whereas, 16 days after plasma radiation, tumor size did not significantly change as compared to 
the first day of treatment (P > 0.05). Drug treatment of the animals also significantly prevented the increase in 
tumor size (Compered to day 0, P > 0.05). Moreover, after the plasma treatment the survival rate of the animals 
was followed up for 24 days. Plasma treatment led to the survival of about 40% of the mice until the last day of 
observation; whereas, this amount was 60% in the drug treated group (Fig. 4b).
Plasma affects the cells in the tumor area. To investigate histological differences between treated and 
control tumors, we performed H&E staining of the tumor sections (Fig. 5). Although control tumors exhibited a 
homogeneous distribution of viable cells, the sections of the plasma and drug treated tumors showed shrinkage 
of the cells, nuclear condensation and fragmentation which are indicative of apoptosis.
Figure 2. Cell migration assessment by wound healing assay, 24 hours after the plasma and drug 
treatments. The magnification of the images is 40X. (* * P < 0.01).
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Plasma induces apoptosis in the tumor cells. Figure 6 indicates the presence of the apoptotic cells in 
tumor tissue 48 hours after the plasma treatment. Results of TUNEL assay suggested that about 13% of the cells 
underwent apoptosis on a cross-section of tumor tissue after plasma radiation (t(10) = 1.81, compared to the 
untreated group, P < 0.05). whereas, 17% of cells underwent apoptosis in drug treated group (t(10) = 1.81, com-
pared to the untreated group, P < 0.05).
Plasma increases P-53 level and Bax/Bcl-2 ratio. Figure 7a shows the expression of p-53, Bax, and 
Bcl-2 in tumor cells. Results suggest that plasma treatment significantly increased the expression of p-53 
(Increment factor: 3.5, t(10) = 2.76, P < 0.01). The increase in p-53 expression in the case of drug treatment, com-
pared to the untreated group, is also significant. (Increment factor: 2, t(10) = 1.81, P < 0.05).
Figure 3. (a) Flow cytometry analysis of plasma and drug treated cells. The percentage of the cells in each 
region is indicated (* * * P < 0.001 and * P < 0.05). (b) Cell cycle analyses. The percentage of the cells in different 
phases of the cell cycle is indicated.
Figure 4. (a) Tumor volume measurements during the 24 days after plasma and drug treatments compared to 
the control group (* * * P < 0.001 and * * P < 0.01). (b) Survival rate of the animals in 24 days after plasma and 
drug treatments.
Figure 5. Hematoxylin and Eosin staining of the tumor tissue. The images show the depth of 2–3 mm of the 
tumor surface which clearly demonstrates the adverse effects of the drug and also the plasma on the cells.
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Increase in the Bax/Bcl-2 ratio in tumor cells treated with plasma is another finding which is of great impor-
tance. This amount increases further in the plasma treatment group compared to the control group (Increment 
factor: 2.8, t(10) = 2.76, P < 0.01). The increment factor reaches to 2.4 for drug treatment group (t(10) = 2.76, 
P < 0.01).
Figure 6. TUNEL assay for detection of apoptosis in the tumor tissue. The images show the depth of 2–3 mm 
of the tumor surface. Overlay images are made by merging of TUNEL and DAPI staining images. The scale of 
the images is 100 μ m. The percentage of the apoptotic cells is compared to the untreated group (* P < 0.05).
Figure 7. (a) Western blot analysis to determine the expression of Bax and Bcl–2 in extracts from tumor cells in 
each treatment group. Ctrl: Untreated group, Plasma: Plasma treated group, Drug: Doxorubicin treated group. 
Compared to the control group (* * P < 0.01 and * P < 0.05). (b) Nitric oxide concentration in the blood of the 
animals (* ) compared to the control group (* P < 0.05).
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Nitric Oxide level increases after the plasma treatment in the blood of the animals. Figure 7b 
represents the amount of nitric oxide in blood of the mice. This diagram shows that the amount of nitric oxide in 
the blood increased three times in plasma treated group compared to the control group. This increase is 2.8 times 
in the case of doxorubicin treated group.
Discussion
This study is among the initial advances in the use of cold atmospheric plasma inside the body of a living animal. In-vitro 
results showed that the plasma initially developed apoptosis in 4T1 cells (breast cancer cell line), and also inhibited the 
cell metastasis. The in-vivo study revealed that the μ -plasma treatment stopped the tumor growth. The findings also 
indicated that the plasma caused apoptosis in the tumor cells through the activation of the p-53 and Bax/Bcl-2 proteins.
By focusing on the cellular events, the results revealed that the plasma treatment could stop the cancer cells in 
Sub G1 phase, and could prevent them from entering into the DNA segmentation phase. Thus, more than 80% of 
the cancer cells which were treated with the plasma radiation underwent the apoptosis. This result is in agreement 
with the findings of many previous studies1,3,31,32. Partecke et al.33 observed that the argon plasma jet induced 
about 80% cell death which is comparable with the results of the present study. However, this study showed that 
the μ -plasma jet could lead to apoptotic death in the cancer cells.
Among all the in vivo plasma treatment studies, there are few reports which showed the design and optimiza-
tion of the μ -plasma jet for utilizing in the patient’s body. One of the most important concerns about the μ -plasma 
jet is the temperature of the plasma jet plume, as the elevated temperature may cause the physical damage to the 
normal tissue. Zou et al.28 optimized the temperature of the μ -plasma jet by using the resistor and controlled the 
temperature of the plasma region. The low temperature of the plasma (less than 35 °C) in the present study associ-
ated by the high electron density could guarantee that the reactive species in the cold plasma could react with the 
tumor cells without any temperature hazard. The H&E staining showed that the plasma affected the tumor cells. 
In the analysis of the surface of the plasma treated tumors, the absence of the crust and of necrotic areas suggests 
little or no thermal impairment (data not shown) which is in conjunction with the results of in vitro experiments.
As mentioned earlier, few studies have been performed on the in vivo effects of plasma33–35. However, the 
majority of them have radiated the plasma from outside of the body. Van Damme et al.36 have shown that plasma 
exposure for 2 minute and 3 times in each treatment session by Dielectric Barrier Discharge (DBD) can decrease 
the size of glioma xerograph by 30%. The present research indicated that the in-situ plasma treatment could 
suppress the tumor growth until 24 days after the plasma treatment. In this regard, Kidar et al.22 showed the 
growth suppression of bladder (SCaBER) tumor by 5 minutes plasma treatment. They demonstrated that the 
plasma treatment could extend the life-span of the cancerous animals which is also in agreement with the results 
of this study. However, the death of animals in the plasma and drug treated group during the period of 24 days of 
observation, may be due to the other factors such as infection of the animals due to the low systemic immunity of 
the animal or the migration of the cancer cells to another organs37. Moreover, our results showed that the plasma 
treatment led to comparable results with those of the conventional chemotherapy drug treatment.
This study showed that the μ -plasma jet could inhibit the tumor growth in one plasma radiation session that 
lasted for 3 minutes. The differences in the effective treatment time between this study and other studies may be 
attributed to the differences in the sources, including the direct impact of the plasma ROS on the tumor as the 
most probable reason. When plasma is radiated from outside of the body, skin may act as a barrier that prevents 
such reactive and unstable species to reach the tumor tissue; whereas, in the μ -plasma method, these species 
can reach the tumor easily and trigger several chemical reactions, leading to a greater population of apoptotic 
cells. In addition, Collet et al.38 study showed an increase in the amount of nitric oxide in the blood after plasma 
treatment which is conjunction with our study. Yan et al.39 proved that the increase in the amount of the ROS and 
nitric oxide were correlated with the increase of the cell death by the lipid peroxidation in the cell membrane. The 
reactive species in the atmospheric plasma such as OH, NO, O, N2+ may cause the production of intracellular 
ROS40. The balance between the extent of the induced oxidative stress and the anti-oxidative mechanisms in the 
cells would render the cells toward death or survival41.
There are several methods which are now being in use for the cancer treatment such as chemotherapy42, sur-
gery43 and radiotherapy44. The conventional methods have some disadvantages such as low rapidity and high cost 
of treatment. Moreover, adverse effects for both the operator and the patient are another disadvantages for such 
methods. While the plasma treatment may overcome the adverse effects of the traditional treatments, it should 
be noted that the plasma can be considered as a local treatment tool and does not exert the systemic therapeutic 
effects like chemical drugs. This seems to be a major issue for the plasma therapy for patients in clinical stage.
In summary, this study showed the effect of 250 micron non-thermal plasma jet inside the animal body on 
the suppression of the tumors growth. The in-vitro results showed that the μ -plasma could induce apoptosis in 
the 4T1 breast cancer cells and could inhibit the migration of the cells. The in-vivo results demonstrated that the 
μ -plasma suppressed the tumor growth and induced apoptosis in the tumor cells. The results of this study is a 
primary research for utilizing the atmospheric pressure plasma inside the patient’s body in the future.
Material and Methods
Ethics statement. All animal maintenance and procedures were in accordance with recommendations 
established by the Animal Ethics Committee of Tarbiat Modares University, Faculty of Medical Sciences as well as 
the United States NIH guidelines (publication no. 85-23). The protocols were approved by the Ethics Committee 
of Tarbiat Modares University, Faculty of Medical Sciences. All surgeries were performed under deep anesthesia, 
and all efforts were made to minimize suffering.
Plasma setup and characterization. The μ -plasma jet consisted of a 30 cm long and 3 mm thick Nelaton 
catheter. At the end of the catheter, a 250 μ m capillary tube (length = 5 cm) were attached and insulated by epoxy. 
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A copper wire were inserted into the catheter downward up to 2 cm from the capillary tube. The copper wire 
connected to the high voltage power supply. The power of the electrode was driven by a 6 KHz pulsed DC (Duty 
cycle = 20%) with the voltage of the 4 kV. The feeding gases for this study were 99.999% pure helium (He) which 
was injected into the catheter with 0.5 lit/min gas flow rate. The plasma plum exits from the capillary tube by the 
ionization of the gas (Fig. 8a).
For plasma characterization, first the emitted light from the plasma was collected by AvaSpec –ULS 2048 
(Avantes Co, NL) spectrometer. The spectrum of the irradiated light was collected from 200–1100 nm with optical 
resolution of 0.1 nm. In order to evaluate the temperature of the ions and the electrons, the second positive system 
transition (370 nm to 382 nm) which obtained from the plasma spectrum was analyzed by SpecAir software. The 
temperatures of ions and electrons are figured out by equality of rotational and vibrational temperatures respec-
tively. Finally the electron density of the plasma can be evaluated by analyzing the Hα transition at 658 nm by the 
procedure which has been discussed in the previous study45.
Cell culture and plasma treatment. The mouse metastatic breast cancer 4T1 cells (ATCC CRL 2339, 
Pasteur institute, IR) were cultured in RPMI-1640 (Gibco Co, USA) supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Gibco CO, USA), 100 U/ml penicillin and 100 μ g/ml streptomycin (Sigma- Aldrich, USA) in a 
humidified incubator supplied with 5% (v/v) CO2 at 37 °C. Doxorubicin (Sigma-Aldrich, USA) at the concentra-
tion of 0.5 μ g/ml as a conventional chemotherapy drug46 was employed as a potent apoptotic agent. The dosage 
of the drug was obtained from the previous studies13,47. The plasma was exposed to the cells for 1 minute and 
the distance between the cultured cells and the micro-plasma jet tip was set to 1 cm in all in-vitro experiments. 
Moreover, no significant changes in temperature were observed during the plasma treatment. All the in-vitro 
experiments were repeated for 3 times.
Wound healing Assay. 1 × 105 cells/well of 4T1 were cultured in 6 well culture plates. After the cells attached 
as a monolayer and reached the confluency of 70–75%, the cells of each well were scratched and then treated with 
plasma for 1 min and examined after 24 h following the plasma treatment. The cell migration to the scratched area 
was examined with inverted microscope. In order to quantify the cell migration in the wound healing assay the 
ImageJ software was employed under the standard protocol48.
Flow cytometry analysis. Apoptotic cells were quantified by annexin V-FITC and Propidium iodide (PI) 
double staining, using an annexin V-FITC apoptosis detection kit (Sigma-Aldrich, USA) according to manu-
facturer’s protocol. 5 × 104 cells/well of 4T1 were seeded into 12 well flat plates. After the confluency of 70% was 
reached, the media was aspirated and the cells were washed with phosphate buffered saline (PBS), then the cells 
were treated with plasma and examined 24 h after the plasma treatment. Trypsinized 4T1 cells were collected and 
washed twice with PBS, centrifuged at 2000 RPM for 5 minutes and added 500 μ l of the binding buffer. Then, 5 μ l 
of Annexin V–FITC and 5 μ l of PI were added and the cells were gently vortexed. Cells were then incubated for 
15 minutes at room temperature (25 °C) in the dark. Finally, the cells were analyzed by flow cytometer (Becton 
Dickinson, USA).
Figure 8. (a) Real discharge photo of μ -plasma jet. (b) Utilizing the μ -plasma jet inside the rat’s body.  
(c) Schematic of using μ -plasma jet inside the animal’s body.
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Cell cycle analysis. 4T1 cells (1 × 105 cells/well) were cultivated in 6 well plates. After reaching 70% of con-
fluency, the media was removed, the cells were washed with PBS, treated with plasma and examined 36–38 h after 
the plasma treatment. Then the cells were harvested and washed by PBS and then 800 μ l of cold 75% ethanol was 
added drop wisely to the cells while pipetting to minimize clumping of the cells. The cells were kept for15 min-
utes on ice. Ethanol-fixed cells were washed twice with PBS and then 300 μ l of the solution containing 10 μ PI 
(Sigma-Aldrich, USA) (1 mg/ml), 1 μ triton X-100 (Sigma-Aldrich, USA), 20 μ l RNase A (CinnaGen, IR) in 1 ml 
PBS, were added to the cells. Samples were incubated for 15 min at room temperature in the dark and were ana-
lyzed by flow cytometer (Becton Dickinson, USA).
Animal study. 1 × 106 4T1 cells in PBS were injected subcutaneously to 15 female BALB/c mice aged 4–6 
weeks with the average weight of 20 ± 5 gr (Purchased from Pasteur institute, IR). Mice divided into three groups 
(control, treated with plasma, treated with doxorubicin) and each group consists of 5 mice. After the tumor 
size reached 5 ± 0.2 mm the skin of the animals of the first group, at a distance of 1.5 cm from the tumor edge, 
were drilled by sterile blade to make a hole with the diameter of about 0.5 mm. The plasma probe was injected 
subcutaneously through the hole. In addition, a capillary tube inserted subcutaneously to the other side of the 
tumor to evacuate the gas (Fig. 8b for real image and Fig. 8c for schematic presentation). The plasma was exposed 
to the tumor for 3 minutes at one session. In the drug treated group the mice were administered doxorubicin 
at the dosage of 5 mg/kg. The third group received no treatments. Tumor volumes were calculated by formula 
V = 0.52 × (X2Y) every two days and the study was followed for 24 days. It should be noted that all of the pro-
cedures were done under the full anesthesia by intra-peritoneal injection of ketamine (100 mg/kg) and xylazine 
(10 mg/kg) (Alpha Co., IR). It’s notable to state that the animals in the control group were also under anesthesia 
for the same period of time.
TUNEL assay- Hematoxylin and Eosin staining. Apoptotic tumor cells were determined by terminal 
deoxynucleotidyl transferase- deoxyuridine triphosphate nick end labeling (TUNEL) staining (In Suit Cell Death 
Detection Kit, Fluorescein, Roche, CH). In this regard, 48 hours after the plasma treatment, half of the tumors 
were extracted from the animals 48 h after the plasma or drug treatment. The tumor was fixed in 4% formalde-
hyde in PBS for 24 h and embedded in paraffin for sectioning. The tumor sections were adhered to the glass slides 
pretreated with 0.01% aqueous solution of poly-L-lysine. The slides were heated at 60 °C followed by washing in 
xylene and rehydration through a graded series of ethanol. Finally the TUNEL staining of the samples were fol-
lowed according to the manufacturer protocol and the slides were observed under the fluorescence microscopy 
and the images were processed by ImageJ software49. Moreover, Hematoxylin and eosin (H&E) staining were used 
to reveal the histopathological changes of the tissue.
Western blotting. For western blotting analysis half of the tumors were collected from the animals. 
Extraction of proteins from samples were performed by RIPA buffer (10 mM Tris–HCl, pH 7.4, 150 mM NaCl, 
5 mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate and 0.5% Sodium deoxycholate) containing protease 
and phosphatase inhibitor cocktails. Protein concentrations were examined by Bradford assay50. Equal amounts 
of the total proteins were run on 12% Sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE assay) and trans-
ferred to the polyvinylidene difluoride (PVDF) and then probed with specific primary antibodies including 
rabbit polyclonal anti-Bax (1:200), mouse polyclonal anti-Bcl2 (1:200), rabbit polyclonal anti-P53 proteins 
(1:200) (Santa Cruz Biotechnology, USA) and secondary antibodies conjugated with horse radish peroxidase 
(HRP) (Cell Signaling Technology, USA). β-Actin was used as the control. Blots were developed by using DAB 
(Diaminobenzidine) staining.
Nitric oxide (NO) concentration assay. The blood of the animals were collected 48 hours after the plasma 
treatment, and the plasma was obtained by centrifugation of the whole blood. The serum samples were stored 
at − 70 °С until the NO assay was performed. Briefly, nitrite concentration was determined, using the standard 
Griess reagent by adding 50 μ l of the test solution to 96-well flat-bottomed plates containing 50 μ L of Griess 
reagent (Promega Co., USA). The absorbance of each well was measured by microplate reader (BioTeK, USA) at 
540 nm and the nitrite concentration was determined by comparing the optical density at 540 nm (OD540) with 
a standard curve (1 to 200 μ M) by the standard protocol51.
Statistical analyses. Results were expressed as mean ± standard deviation (SD) of the wound area and 
calculated by GraphPad Prism Software. Student t-test was used for comparing the plasma and drug treated and 
untreated groups. In addition, one way-ANOVA test was employed to compare the mean of each group with 
that of the control mice in plasma and drug treatments for the tumor volume measurements and survival tests. 
In this regard, t (a) and F (a,b) refer to the critical t value and F distribution respectively. The F distribution is a 
right-skewed distribution and mostly employed in analysis of variance and critical t value is for estimating the 
mean of a normally distributed population in situations. These functions show the validity of the hypothesis in 
each comparison in addition to P value. It should be noted that, P-values < 0.05 (* ) were considered as significant.
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